Literature DB >> 23291824

Monoclonal gammopathy of undetermined significance associated with blue finger syndrome.

Alaa M Ali1, Aibek E Mirrakhimov.   

Abstract

An 86-year-old Caucasian woman with a medical history of monoclonal gammopathy of undetermined significance (MGUS) was admitted to the hospital with a chief complaint of sudden onset of bluish discolouration of the fifth left hand digit. On a physical examination, cyanosis of the fifth digit of the left hand was noticed with decreased capillary fill but no ulcers. The patient had no tenderness on palpation. Pulses were palpable over the radial arteries bilaterally. Patients with MGUS may be at increased risk of thromboembolic disease. A clear explanation for this association in these patients is not currently known. This case report highlights the association between MGUS and thromboembolic events, particularly blue finger syndrome.

Entities:  

Mesh:

Year:  2013        PMID: 23291824      PMCID: PMC3603850          DOI: 10.1136/bcr-2012-007966

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  19 in total

Review 1.  Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence.

Authors:  S Vincent Rajkumar; Robert A Kyle; Francis K Buadi
Journal:  Mayo Clin Proc       Date:  2010-10       Impact factor: 7.616

2.  Venous thromboembolism in patients with monoclonal gammopathy of undetermined significance.

Authors:  Alaa A Muslimani; Timothy P Spiro; Asif A Chaudhry; Harris C Taylor; Ishmael Jaiyesimi; Hamed A Daw
Journal:  Clin Adv Hematol Oncol       Date:  2009-12

3.  Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study.

Authors:  Sigurdur Y Kristinsson; Ruth M Pfeiffer; Magnus Björkholm; Lynn R Goldin; Sam Schulman; Cecilie Blimark; Ulf-Henrik Mellqvist; Anders Wahlin; Ingemar Turesson; Ola Landgren
Journal:  Blood       Date:  2010-03-18       Impact factor: 22.113

4.  Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.

Authors:  M Zangari; E Anaissie; B Barlogie; A Badros; R Desikan; A V Gopal; C Morris; A Toor; E Siegel; L Fink; G Tricot
Journal:  Blood       Date:  2001-09-01       Impact factor: 22.113

5.  Monoclonal gammopathy of undetermined significance and risk of venous thromboembolism.

Authors:  Henrik Gregersen; Mette Nørgaard; Marianne T Severinsen; Malene C Engebjerg; Paw Jensen; Henrik T Sørensen
Journal:  Eur J Haematol       Date:  2010-12-22       Impact factor: 2.997

Review 6.  Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.

Authors:  R A Kyle; B G M Durie; S V Rajkumar; O Landgren; J Blade; G Merlini; N Kröger; H Einsele; D H Vesole; M Dimopoulos; J San Miguel; H Avet-Loiseau; R Hajek; W M Chen; K C Anderson; H Ludwig; P Sonneveld; S Pavlovsky; A Palumbo; P G Richardson; B Barlogie; P Greipp; R Vescio; I Turesson; J Westin; M Boccadoro
Journal:  Leukemia       Date:  2010-04-22       Impact factor: 11.528

7.  Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.

Authors:  Maurizio Zangari; Eric Siegel; Bart Barlogie; Elias Anaissie; Fariba Saghafifar; Athanasios Fassas; Christopher Morris; Louis Fink; Guido Tricot
Journal:  Blood       Date:  2002-08-15       Impact factor: 22.113

8.  Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease.

Authors:  Gordan Srkalovic; Marte G Cameron; Lisa Rybicki; Steven R Deitcher; Kandice Kattke-Marchant; Mohamad A Hussein
Journal:  Cancer       Date:  2004-08-01       Impact factor: 6.860

9.  UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS).

Authors:  Jenny Bird; Judith Behrens; Jan Westin; Ingemar Turesson; Mark Drayson; Robert Beetham; Shirley D'Sa; Richard Soutar; Anders Waage; Nina Gulbrandsen; Henrik Gregersen; Eric Low
Journal:  Br J Haematol       Date:  2009-08-10       Impact factor: 6.998

10.  Review of 1027 patients with newly diagnosed multiple myeloma.

Authors:  Robert A Kyle; Morie A Gertz; Thomas E Witzig; John A Lust; Martha Q Lacy; Angela Dispenzieri; Rafael Fonseca; S Vincent Rajkumar; Janice R Offord; Dirk R Larson; Matthew E Plevak; Terry M Therneau; Philip R Greipp
Journal:  Mayo Clin Proc       Date:  2003-01       Impact factor: 7.616

View more
  1 in total

1.  Multiple Myeloma Mimicking a Small Vessel Vasculitis Presentation.

Authors:  Mateo Mejía-Zuluaga; Jorge Andrés Lacouture; Maria Clara Gaviria; Maria Adelaida Garcés; Ana María Mejía; Sebastián Herrera
Journal:  Case Rep Rheumatol       Date:  2020-02-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.